NCT04807959 is a clinical trial of 20Lighter anti-obesity program in Obesity, sponsored by 20Lighter.

Who is sponsoring NCT04807959?

NCT04807959 is sponsored by 20Lighter.

What drugs are being tested in NCT04807959?

Interventions in NCT04807959: 20Lighter anti-obesity program.

What condition does NCT04807959 study?

NCT04807959 studies Obesity, Obesity, Morbid, Obesity, Visceral, Central Obesity, Metabolic Disease, Hypertension, Dyslipidemias, Type 2 Diabetes, Visceral Obesity.

Is NCT04807959 still recruiting?

NCT04807959 is currently completed. Last updated 22 March 2021.

Last reviewed 2021-03-22 · How we verify

NCT04807959

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program

Completed Last updated 22 March 2021

What this trial tests

trial testing 20Lighter anti-obesity program in Obesity in 2,200 participants. Completed in 9 October 2018.

Timeline

27 October 2016

Primary endpoint
1 October 2018

9 October 2018

Quick facts

Lead sponsor	20Lighter
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,200
Start date	27 October 2016
Primary completion	1 October 2018
Estimated completion	9 October 2018

Drugs / interventions tested

20Lighter anti-obesity program

Conditions studied

Obesity — all drugs for Obesity →
Obesity, Morbid — all drugs for Obesity, Morbid →
Obesity, Visceral — all drugs for Obesity, Visceral →
Central Obesity — all drugs for Central Obesity →

Sponsor

20Lighter

Who can join

Adults 18 to 80, any sex, with Obesity or Obesity, Morbid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective review of body composition outcomes of participants of a comprehensive visceral-fat focused anti-obesity program. Data from approximately 2000-2500 participants are expected to be included in the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other 20Lighter trials

Trials by the same sponsor.

NCT05219240 — Evaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04807959 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by 20Lighter
Last refreshed: 22 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04807959.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing